Product News from the May 20 MM&M News Brief

Share this article:

Product News
The FDA granted traditional approval status to GlaxoSmithKline's Trizivir (abacavir sulfate, lamivudine and zidovudine) for the treatment of HIV infection. Trizivir is the first and only FDA-approved, fixed-dose-combination drug for HIV that combines three drugs into one tablet, GSK said.

Roche has decided to discontinue the sale and distribution of its HIV medication Fortovase (saquinavir), as clinical demand for the drug has declined significantly due to the availability of a new formulation of Invirase (saquinavir mesylate). The removal of Fortovase, which will be discontinued during the first quarter of 2006, is completely voluntary and is not due to safety or efficacy issues, Roche said.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions